Monoclonal Antibodies Market

Monoclonal Antibodies Market Size (2022 to 2027)

As per our report, the size of the global monoclonal antibodies market was worth USD 39.10 Billion in 2022. This figure is estimated to be growing at a CAGR of 5.30% and will reach USD 50.62 Billion by 2027.

In biochemistry and molecular biology, monoclonal antibodies play an important role in detecting or purifying substances. These are derived from identical immune cells and can easily bind to a particular antigen. Hybridoma technology is designing monoclonal antibodies that will enhance the immunity system naturally. It is approved by the U.S Food and Drug Administration (FDA) as it is an innovative product in molecular biology for disease treatment. Many global companies are focusing on developing molecular agents to treat various diseases like cancer. 

Impact of COVID-19 on the global monoclonal antibodies market:

The outburst of COVID-19 has brought the world to a standstill. This health crisis has brought an unprecedented impact on businesses in every sector, including the healthcare sector. The COVID-19 impact has positively influenced the monoclonal antibodies market as these antibodies prevent and treat early infections of COVID-19. Many companies are in a race to find an efficient vaccine to treat novel coronavirus disease with the help of monoclonal antibodies. Government organizations support the researchers by approving the emergency utilization of the new products to treat this disease. In addition, many monoclonal antibodies licensed or in developing other illnesses are in clinical trials to check whether they affect COVID-19 patients.

MARKET DRIVERS:

Increasing incidences of chronic diseases such as cancer, diabetes, and others worldwide is undoubtedly a key factor for the worldwide monoclonal antibodies market to grow.

The rise in the demand to ensure quality healthcare services is accelerating the market's growth. Also, the invention of new monoclonal antibody applications significantly influences this market's growth rate. Furthermore, the rise in healthcare infrastructure investment is likely to boost the global mABs market demand. The development of new molecules is expected to play a prominent role in the market's future due to this technology's cost-effectiveness.

The advancement of genomics research and development activities and the emergence of technologically advanced genetic platforms, such as next-generation sequencing, have contributed significantly to the market and helped the existing companies in the global mABs market grow further.

The emergence of advanced technology, the launch of innovative products in the biotechnology field, and growth in the economy in developed and developing countries are surging the demand for the monoclonal antibodies market. Growing knowledge of genomics, the trend toward next-generation sequencing, and ease in the availability of various resources used in the research centers fuel the market's demand. The rise in awareness of the therapies and other biological parameters impacts the market's growth.

MARKET RESTRAINTS:

However, less availability of raw materials used to manufacture drugs restrains the market's demand. In addition, the lack of sufficient knowledge in rural areas is slowly hindering the growth rate of the global monoclonal antibodies market.

One of the other major challenging factors for the monoclonal antibodies market is the shortage of skilled labor. It is due to fewer training programs in the biotechnology field. In addition, the equipment used in the laboratories is high in cost, and small-scale organizations cannot afford them, which is also one of the factors impeding the demand of the mABs market.

REPORT COVERAGE:

This research report on Global Monoclonal Antibodies Market has been segmented and sub-segmented based on the source, indication, end-user, application, and region.

Monoclonal Antibodies Market - By Source:

• Murine
• Chimeric
• Humanized
• Human

Based on the source, the murine segment held the largest share of the global monoclonal antibodies market in 2021, whereas the chimeric segment is expected to have the highest growth rate in the coming years. An increasing number of people suffering from various health disorders is a specific factor for this segment to grow.

On the other hand, the humanized monoclonal segment is one of the most lucrative segments and is expected to grow at a healthy rate during the forecast period. The extensive adoption of innovative techniques for treating various diseases such as cancer and inflammatory disorders is propelling the demand of this segment. In addition, progressive genetic engineering technology engaged in its production is one of the significant factors driving the segment demand.

The human monoclonal antibodies segment will have rapid growth during the forecast period. 

Monoclonal Antibodies Market - By Indication:

• Cancer
  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Other)

Based on the indication, the cancer disease segment is ruling the market currently and accounted for a dominating share of the mABs market in 2021. Adopting sedentary lifestyles and changing food habits are some attributes for the cancer segment to grow. Therefore, this segment is expected to continue its dominance throughout the forecast period. The segment growth is further majorly driven by the high increase in the incidence of cancer and healthcare reimbursement policies. In addition, intensifying drug pipeline integrated with treatment approvals and clinical trials is projected to generate profitable growth opportunities in the monoclonal antibodies market.

Monoclonal Antibodies Market - By End-User:

• Hospitals/Clinics
• Research Institute
• Diagnostic Laboratories

Based on end-user, the hospitals/clinics are forecasted to register the most significant share of the monoclonal antibodies market and are major to the increasing healthcare centers and clinics' scale. Besides, the growing geriatric population is enhancing the market's growth rate. In addition, the rising patient population and growing chronic diseases in patients are increasing the demand for this segment. Furthermore, this segment is also expected to be favored by increasing chronic ailments, growing healthcare expenses, and raising awareness among the patient population about alternative treatments.

Monoclonal Antibodies Market - By Application:

• Medical
• Experimental
• Western Blot
  • ELISA
  • Radioimmune Assays
  • Immunofluorescence
  • Others

Based on the application, the medical segment is led the monoclonal antibodies market worldwide in 2021, owing to a rise in the number of research and development activities.

The ELISA segment fosters the monoclonal antibody market during the forecast period.

Monoclonal Antibodies Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa

Geographically, North America Monoclonal Antibodies Market is dominating the global market due to the well-established health care infrastructure in this region, the increased importance given to state infection control and management, and the growing prevalence of lifestyle-related health issues. Furthermore, the market will continue to grow during the forecast period, owing to amplified public investments in cancer research and technological development.

The Europe Monoclonal Antibodies Market is predicted to grow at a compound annual growth rate (CAGR %) from 2022 to 2027.

The Asia-Pacific Monoclonal Antibodies Market is also anticipated to increase significantly due to improved lifestyles and increasing awareness about mAbs among patients, advanced research, and development costs. However, due to the lack of penetration, the Asia Pacific market has a high potential to grow during the forecast period.

The Latin America Monoclonal Antibodies Market is predicted to be USD 7.69 billion by 2027, to grow at a CAGR of 9.5% from 2022 to 2027.

The MEA Monoclonal Antibodies Market is witnessed to reach at a CAGR of 12.95% during the forecast period.

KEY MARKET PARTICIPANTS & SHARE INSIGHTS:

Companies leading the global monoclonal antibodies market profiled in the report are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., And Shanghai Junshi Bioscience Co., Ltd.

RECENT DEVELOPMENTS:

• In January 2020, Pfizer announced to launch Bavencio (avelumab) vaccine, which is used to treat cancer patients.
• In February 2020, GlaxoSmithKline plc registered to introduce belantamab mafodotin, which will act upon the B-cell maturation antigen.